Pfizer Inc. (PFE)
Pfizer Could Surprise Again This Earnings Season (Preview)
Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins as lower-margin COVID products fade from its overall revenue mix. The company's pipeline remains robust, with multiple Phase 3 programs and obesity initiatives that could drive long-term growth and offset upcoming patent expirations. Upcoming earnings may exceed expectations again, as analysts remain cautious despite Pfizer's strong track record of outperforming consensus estimates in recent quarters.
Pfizer GLP-1 weight loss drug available for pre-order in China
Pfizer's GLP-1 weight management treatment Xianweiying is available for pre-order in China, a Reuters check on a local e-commerce platform showed, ramping up competition with rivals in a market analysts expect to be worth billions of dollars.
Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says
Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will eventually leave the company as part of the U.S. drugmaker's strategic simplification, according to an analyst note on Monday.
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings
Pfizer PFE is scheduled to report its first-quarter 2026 results on May 5, with investor focus firmly on its oncology portfolio, which contributes roughly 27% of total revenues. Leading cancer therapies in its lineup include Ibrance, Xtandi, Lorbrena, Braftovi/Mektovi, as well as antibody-drug conjugates like Padcev acquired through Seagen.
Pfizer (PFE) Outperforms Broader Market: What You Need to Know
Pfizer (PFE) reached $27.34 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.
Trellus Health shares jump 39% on Pfizer deal renewal
Trellus Health PLC (AIM:TRLS), the digital chronic disease management platform, surged 39% to 0.28p after the company announced it had renewed its licensing agreement with Pfizer. Under the renewed deal, Pfizer will continue to license Trellus Health's patient-support educational content for use in its inflammatory bowel disease (IBD) digital application.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results
Pfizer PFE is one of the largest and most successful drugmakers in oncology with an established presence in breast, genitourinary, thoracic, gastrointestinal cancer and blood cancers. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
Pfizer (PFE) concluded the recent trading session at $27.1, signifying a -2.62% move from its prior day's close.
Why Pfizer (PFE) Outpaced the Stock Market Today
In the most recent trading session, Pfizer (PFE) closed at $28.55, indicating a +1.67% shift from the previous trading day.
PFE Stock Trades Above 200 & 50-Day SMA for 3 Months: How to Play
Pfizer's PFE stock has been trading steadily above its 50-day and 200-day simple moving averages (SMAs) since early January, signaling sustained investor confidence. The stock is also up about 12.8% so far in 2026.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
